Please refer to relevant product direction for use for complete list of indications, contraindications and warnings. *Based on global Clareon® PanOptix® and AcrySof® PanOptix® unit sales 2021-2022 †Pooled binocular defocus curve data from six individual studies. Snellen VA was converted from logMAR VA. A Snellen notation of 20/20^-2 or better indicates a logMAR VA of 0.04 or better, which means ≥3 of the 5 ETDRS chart letters in the line were identified correctly. 1. Market Scope 2022 IOL Market Report 2. Alcon data on file, REF-18881, 2022 3. Clareon® PanOptix® Directions for Use_09/2021 4. Modi et al. Visual and Patient-Reported Outcomes of a Diffractive Trifocal Intraocular Lens Compared with Those of a Monofocal Intraocular Lens. 2020 Sep 28;S0161-6420(20)30677-1 5. Alcon data on file, REF-17351, 2022 6. Lwowski C, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive EDOF and trifocal intraocular lenses. J Cataract Refract Surg 2021 Aug 18. doi: 10.1097/j.jcrs.0000000000000780 This content is intended for Healthcare Professionals only, not for general public ©2023 Alcon Inc. 04/23 ASIA-CPO-2300002 PanOptix® is the most implanted trifocal IOL worldwide and delivers an excellent high-quality visual experience from far to near, with 99% patient satisfaction. 1-4* NO ON E D R E AM S O F S I L VE R 20/20 VISION AT ALL DISTANCES4,† NATURAL FOCAL POINT OF 60CM 5,6 >9/10 PATIENTS ARE SPECTACLE INDEPENDENT5
RkJQdWJsaXNoZXIy Njk2NTg0